The QualityStocks Daily Wednesday, July 6th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(RFP) $20.3600 +63.01%

QualityStocks(THMO) $0.3022 +30.82%

MarketClub Analysis(BMIX) $0.0140 +18.64%

The QualityStocks Daily Stock List

Resolute Forest Products, Inc. (RFP)

The Online Investor, MarketBeat, Marketbeat.com, InvestorPlace, Trades Of The Day, TradersPro, MarketClub Analysis, BUYINS.NET, Super Stock Picker, StreetInsider, Daily Trade Alert, StockMarketWatch, Energy & Resources Digest, AllPennyStocks, Street Insider, Zacks, StreetAuthority Daily, The Street and QualityStocks reported earlier on Resolute Forest Products, Inc. (RFP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Resolute Forest Products, Inc. (RFP) is a worldwide leader in the forest products industry. The Company has a varied range of products. These include market pulp, tissue, wood products, newsprint, as well as specialty papers. Resolute’s strategy centers on continuing to transform the Company away from mature markets and declining products toward a more profitable and sustainable organization over the long run, founded on a competitive portfolio of manufacturing assets and a strong presence in long-term growth markets. Resolute Forest Products has its corporate office in Montréal, Quebec.

The Company’s products are marketed in close to 70 countries. Resolute Forest Products owns or operates approximately 40 facilities, and power generation assets, in the USA and Canada. The Company has third-party certified 100 percent of its managed woodlands to globally recognized sustainable forest management standards.

Resolute Forest Products is a top producer of lumber and other wood products for the residential construction and home renovation markets, and also for specialized structural and industrial applications. Moreover, the Company is one of the few producers capable of supplying a broad array of grades of market pulp.

Additionally, Resolute has an integrated tissue business. It offers a range of quality products for retail and professional markets. Furthermore, the Company’s portfolio of specialty papers features a wide range of uncoated mechanical papers. These offer a solution for almost any commercial printing application.

Resolute is also a foremost international producer of newsprint. It has mills strategically located to serve major markets throughout North America and worldwide.

Resolute Forest Products, Inc. (RFP), closed Wednesday's trading session at $20.36, up 63.0104%, on 13,353,090 volume. The average volume for the last 3 months is 13.202M and the stock's 52-week low/high is $9.84/$20.71.

PhaseBio Pharmaceuticals (PHAS)

StockMarketWatch, QualityStocks, MarketClub Analysis, Kiplinger Today, BUYINS.NET, StreetInsider, Schaeffer's, MarketBeat, InvestorsUnderground, TradersPro and PoliticsAndMyPortfolio reported earlier on PhaseBio Pharmaceuticals (PHAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) (FRA: 2K4) is a clinical-stage biopharmaceutical firm that is engaged in developing and commercializing new therapies for cardiopulmonary ailments.

The firm has its headquarters in Malvern, Pennsylvania and was incorporated in 2002, on January 10th by Clay Bernardin Thorp and Ashutosh Chilkoti. It serves consumers in the United States.

The company is committed to developing new and improved drugs. It uses its recombinant biopolymers to enhance the activity, bioavailability, stability and ease of administration of peptides and proteins. Its aim is to achieve better patient compliance, fewer side effects and higher potency. The company is party to a co-development agreement with SFJ Pharmaceuticals X Ltd, which entails the development of a reversal agent known as PB2452, for an anti-platelet therapy dubbed ticagrelor.

The enterprise’s product pipeline comprises of a formulation known as PB6440, which has been developed to treat resistant hypertension; and a vasoactive intestinal peptide dubbed PB1046, which is in phase 2b clinical trials evaluating its effectiveness in treating pulmonary arterial hypertension. In addition to this, the enterprise develops a reversal agent for the anti-platelet therapy ticagrelor, known as PB25452 (bentracimab). This formulation is in phase 3 clinical trials testing its efficacy in treating patients with life-threatening bleeding events or those that require emergency surgeries.

The company is focused on advancing its bentracimab formulation, which may soon be approved for commercialization for patients in dire need of an antiplatelet reversal agent. The formulation’s success will have a positive impact on investments into the company as well as its growth.

PhaseBio Pharmaceuticals (PHAS), closed Wednesday's trading session at $0.8002, up 21.4264%, on 727,792 volume. The average volume for the last 3 months is 726,094 and the stock's 52-week low/high is $0.4999/$4.10.

ThermoGenesis Holdings (THMO)

BUYINS.NET, StockMarketWatch, QualityStocks, StocksEarning and MarketClub Analysis reported earlier on ThermoGenesis Holdings (THMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ThermoGenesis Holdings Inc. (NASDAQ: THMO) (FRA: THRP) is a healthcare firm that is focused on the development, commercialization and marketing of various automated technologies for CAR-T therapies as well as other cell-based therapies.

The firm has its headquarters in Rancho Cordova, California and was incorporated in 1986 by Philip H. Coelho and David Demirjian. Prior to its name change in November 2019, the firm was known as Cesca Therapeutics Inc. It operates as part of the healthcare/life sciences sector and serves consumers around the globe.

The company operates through the clinical development and device segments. The former segment uses autologous stem cell-based therapeutics while the latter segment is involved in developing and commercializing automated technologies for bioprocessing and cell-based therapeutics.

The enterprise manufactures and markets an automated cryogenic storage and liquid nitrogen controlled-rate-freezing system dubbed the BioArchive Automated Cryopreservation system, which has been designed for cord blood samples and cell therapeutics with clinical applications; and an automated cell separation system known as the AXP II Automated Cell separation system, which isolates and retrieves stem and progenitor cells from blood in the umbilical cord. It also provides a sterile automated system dubbed the PXP point-of-care system, which has been designed to process autologous bone marrow aspirate extracted from stem cells at point-of-care, like in clinics or surgical centers.

The company is focused on pivoting from a device-only firm into a firm that provides the industry with cell-based contract development and manufacturing services. This is in addition to expanding its line of automated cell processing tools.

ThermoGenesis Holdings (THMO), closed Wednesday's trading session at $0.3022, up 30.8225%, on 61,045,315 volume. The average volume for the last 3 months is 61.045M and the stock's 52-week low/high is $0.2013/$3.16.

Matrix Service (MTRX)

StreetInsider, All about trends, MarketBeat, Zacks, Marketbeat.com, The Street, StreetAuthority Daily, Trades Of The Day, SmarTrend Newsletters, INO.com Market Report, Investing Daily, Daily Trade Alert, TraderPower, ProfitableTrading, Big Oil Stocks, BestOtc, Inside Investing Daily, BestChartNow, Barchart, GorillaTrades, InvestorPlace, Penny Sleuth, QualityStocks, Stock Market Watch, StockMarketWatch, The Online Investor, TopStockAnalysts, Total Wealth, Trading Concepts and MarketWatch reported earlier on Matrix Service (MTRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Matrix Service Inc. (NASDAQ: MTRX) (FRA: MX2) is focused on the provision of engineering, construction, infrastructure, fabrication and maintenance services to the minerals, mining, agricultural, industrial, petrochemical, power, gas and oil markets.

The firm has its headquarters in Tulsa, Oklahoma and was incorporated in 1984, on April 4th by Martin Lee Rinehart, Harold Morgan, Doyl D. West and Bill Lee. It operates as part of the engineering and construction industry, under the industrials sector. The firm primarily serves consumers in Australia, South Korea, Canada and the United States.

The enterprise operates through the Storage and terminal solutions, Process and Industrial facilities, and the Utility and power infrastructure segments. The storage segment is involved in engineering, construction and fabrication, repair and maintenance, which includes emergency and planned services, work related to aboveground storage terminals and tanks, and hydrogen, liquid petroleum, liquid oxygen/liquid nitrogen, liquefied natural gas and other specialty vessels. The industrial facilities segment is focused on the fractionating and marketing of natural gas liquids and natural gas, refining of crude oil, and providing plant engineering, industrial cleaning and maintenance services. On the other hand, the utility segment is focused on providing power delivery services, which includes upgrading of existing substations, constructing new substations, distribution upgrades, maintenance, transmission and distribution line installations.

The company recently began the construction of its small-scale boron facility, which will serve as a new production facility for boron for decades to come. This move will facilitate the development of advanced boron materials and open the company up to additional technology partnerships, which will be good for its revenues and investments.

Matrix Service (MTRX), closed Wednesday's trading session at $4.45, off by 2.8384%, on 252,456 volume. The average volume for the last 3 months is 251,093 and the stock's 52-week low/high is $4.2431/$11.76.

Tuniu Corp. (TOUR)

StreetInsider, MarketBeat, Marketbeat.com, Integrity Solution IR, Weekly Wizards, BUYINS.NET, MarketClub Analysis, TraderPower, The Street, PennyStockScholar, INO.com Market Report, InvestorPlace, OTCtipReporter, Profitable Trader Authority, Street Insider, TradersPro, Trading Concepts and Money and Markets reported earlier on Tuniu Corp. (TOUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tuniu Corp. (NASDAQ: TOUR) (FRA: OTUA) is an online leisure travel firm that is focused on providing travel-related services.

The firm has its headquarters in Nanjing, the People’s Republic of China and was incorporated in 2006, by Hai Feng Yan and Dunde Yu. It operates as part of the travel services industry, under the consumer cyclical sector. The firm serves consumers in China.

The company’s mission is to make travel easier for its customers. It has established itself as the top online leisure travel firm in the country, through its dedication and commitment to improving customer experiences. The company generates the majority of its revenues from consumers in China.

The enterprise provides a range of packaged tours, including self-guided and organized tours; as well as other travel-related services like entertainment, meals, pre-arranged itineraries, accommodation reservations, visa application services, tourist attraction tickets, financial services and hotel booking services, as well as bus, train and air ticketing for leisure travelers. It also offers car insurance and rental services, as well as advertising services to tourism bureaus and boards. The enterprise provides its services and products through various offline and online channels, including a call center in Nanjing; a mobile platform; the tuniu.com website; and other retail stores in China.

The firm remains focused on taking on new opportunities, working with its partners and customers to overcome challenges and promoting the development of the travel industry in China. This will positively influence its revenues, help create value for its shareholders while also bolstering its growth.

Tuniu Corp. (TOUR), closed Wednesday's trading session at $1.32, up 6.4516%, on 2,972,355 volume. The average volume for the last 3 months is 2.958M and the stock's 52-week low/high is $0.4555/$2.35.

Kazia Therapeutics (KZIA)

TradersPro, StockMarketWatch, MarketClub Analysis, MarketBeat, QualityStocks and PoliticsAndMyPortfolio reported earlier on Kazia Therapeutics (KZIA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kazia Therapeutics Ltd. (NASDAQ: KZIA) (ASX: KZA) is an oncology-focused biotechnology firm that is focused on the development of anti-cancer drugs.

The firm has its headquarters in Sydney, Australia and was incorporated in March 1994 by Graham Edmund Kelly. Prior to its name change in November 2017, the firm was known as Novogen Ltd. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s objective is to help clinicians and patients confront the most challenging cancers in modern medicine. It draws on the best research available, with its brilliant team harnessing a detailed understanding of the molecular pathways that drive cancer to deliver best-in-class drug candidates. The company’s candidates are designed to treat illnesses like liver cancer, brain cancer and renal cancer.

The enterprise’s product pipeline comprises of a formulation dubbed Cantrixilm to help treat ovarian cancer; and an investigational new drug dubbed EVT801, for the treatment of a range of cancers. EVT801 has been developed to target the formation of new blood vessels around tumors. It also develops a small molecule brain-penetrant of the PI3K/Akt/mTor pathway inhibitor dubbed Paxalisib, which has been developed as a treatment for glioblastoma.

The firm was recently awarded an Orphan Drug Designation for its Paxalisib formulation, for use in treating atypical rhabdoid/teratoid tumors. This move not only benefits patients with said indication but also opens the firm up to new growth opportunities. This is in addition to facilitating the advancement of the therapy.

Kazia Therapeutics (KZIA), closed Wednesday's trading session at $4.11, off by 1.4388%, on 5,519,177 volume. The average volume for the last 3 months is 5.519M and the stock's 52-week low/high is $3.81/$12.28.

Cricut Inc. (CRCT)

Schaeffer's, InvestorPlace, StocksEarning, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, OTCtipReporter, MarketBeat and BUYINS.NET reported earlier on Cricut Inc. (CRCT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cricut Inc. (NASDAQ: CRCT) is focused on designing and marketing a creativity platform that allows users to turn ideas into handmade goods that look professional.

The firm has its headquarters in South Jordan, Utah and was incorporated in June 1969 by Robert Workman. Prior to its name change in March 2018, the firm was known as Provo Craft & Novelty Inc. It operates as part of the computer hardware industry, under the technology sector. The firm serves consumers around the globe.

The company’s mission is to help individuals lead creative lives. It operates through the Subscriptions, Connected machines, Accessories and Materials segments. The company generates most of its revenues from the Accessories and materials segment, via the sale of project materials, machine replacement tools and blades, hand tools and the CricutEasyPress, as well as la carte digital content purchases.

The enterprise provides connected machines, including Cricut Maker, Cricut Explore and Cricut Joy, to create, score, write and cut decorative effects using a range of materials like leather, vinyl and paper. It also designs apps, including Cricut Joy-specific app and Design Space app; and offers Cricut Access and Cricut Access Premium subscription offerings. This is in addition to providing a software which integrates its design apps and connected machines.

The company, which recently announced its latest financial results, is focused on strengthening user onboarding, driving engagement and expanding its presence across new international markets. This will positively influence revenues and investments into the company, while also facilitating the creation of shareholder value.

Cricut Inc. (CRCT), closed Wednesday's trading session at $6.75, up 3.8462%, on 186,309 volume. The average volume for the last 3 months is 186,309 and the stock's 52-week low/high is $5.88/$39.195.

Coda Octopus Group (CODA)

StockMarketWatch, MarketBeat, Small Cap Firm and MarketClub Analysis reported earlier on Coda Octopus Group (CODA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Coda Octopus Group Inc. (NASDAQ: CODA) is focused on the development and sale of underwater technologies and equipment for 3D imaging, mapping, survey and defense applications.

The firm has its headquarters in Orlando, Florida and was incorporated in 1994. It operates as part of the aerospace and defense industry, under the industrials sector. The firm serves consumers around the world, with a focus on those in the Americas, Asia, Europe, the Middle East, Australia and Africa.

The company operates through the Marine engineering business and the Marine technology business segments. The former segment, which is also referred to as the Services segment, is involved in the supply of engineering services mainly to prime defense contractors. On the other hand, the latter segment, which is referred to as the Products segment, is focused on the development of solutions for both the defense and commercial subsea market. The company markets its products under the Coda Octopus brand name.

The enterprise’s solutions include a diver augmented vision display system; Echoscope and Echoscope PIPE used for monitoring cable installations for offshore wind projects in real time; and GNSS-aided navigation systems. It also offers geophysical data acquisition systems and analysis software that are used mainly by research institutions, offshore renewable firms and survey firms.

The company, which recently released its latest financial results, is focused on its Diver Augmented Vision Display division which it believes is a key pillar to its growth strategy. This division will also drive revenue growth and encourage more investments into the company.

Coda Octopus Group (CODA), closed Wednesday's trading session at $5.09, up 1.1928%, on 3,632 volume. The average volume for the last 3 months is 3,632 and the stock's 52-week low/high is $4.75/$9.9044.

Grapefruit USA Inc. (GPFT)

QualityStocks, Stocks to Buy Now, SmallCapRelations, SeriousTraders, NetworkNewsWire, HempWire, CBDWire, CannabisNewsWire, InvestorBrandNetwork, StocksToBuyNow, Kiplinger Today, Pennystockmania and PennyPickGains reported earlier on Grapefruit USA Inc. (GPFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grapefruit USA (OTCQB: GPFT), an innovative California-based cannabiotech company, has executed a binding letter of intention (“LOI”) with Diagnostic Lab Corporation (“DLC”). The letter, which was entered into on June 30, 2022, calls for the two companies to jointly recapitalize Grapefruit and raise $12.5 million of debt financing, which includes $5.5 million already committed from a qualified construction. DLC is a diversified food and agriculture safety company. The funding will be used to complete construction of a cultivation, manufacturing and distribution facility; acquire DLC assets; apply for an FDA 510K approval for GPFT’s patented Hourglass(TM) time release Z-POD THC/CBD/cannabinoid infused delivery cream; and conduct a clinical study to measure the effects of the Hourglass delivery cream on pain and other symptoms suffered by individuals diagnosed with osteoarthritis. “Execution of this letter of intent between DLC and GPFT is the next step in Grapefruit’s evolution from a ‘me-too’ cannabis company to a medical, science-based, canna-focused biotech company that will develop and obtain regulatory approval for an ever-expanding line of proprietary cannabis products based on the company’s patented Hourglass technology,” said Grapefruit CEO and cofounder Bradley J. Yourist in the press release. “Construction of the Coachillin’ ‘mothership’ facility at the Coachillin’ Park will secure our balance sheet and provide a reliable source of reasonably priced pharma-quality cannabis flowers for raw material for THC Hourglass products and for distribution in both the U.S. and Canada, as appropriate under any given market circumstances. The 510K approval for the Hourglass technology will facilitate its rapid market acceptance throughout the United States as an approved medical device. Finally, our lab acquisition program will provide rapid revenue growth and expand the company’s cannabis industry footprint. The parties expect to finalize and execute the definitive agreement before the end of August 2022 and close the transaction shortly thereafter.”

To view the full press release, visit https://ibn.fm/ZhBS2

About Grapefruit USA Inc.

Grapefruit's corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit's extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin' Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. To find out more about the company, please visit https://GrapefruitBlvd.com.

Grapefruit USA Inc. (GPFT), closed Wednesday's trading session at $0.0142, up 5.1852%, on 638,573 volume. The average volume for the last 3 months is 638,573 and the stock's 52-week low/high is $0.013/$0.0579.

Cerberus Cyber Sentinel Corporation (CISO)

We reported earlier on Cerberus Cyber Sentinel Corporation (CISO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cerberus Sentinel (NASDAQ: CISO), a cybersecurity consulting and managed services firm based in Scottsdale, Arizona, today announced that it has completed the acquisition of CyberViking, a cybersecurity company based in Georgia and Oregon. According to the update, CyberViking became a wholly owned subsidiary of Cerberus Sentinel upon closing of the transaction. “With the addition of CyberViking, we take a next step in expanding our international reach as well as broadening our expertise for our cybersecurity health care and industrial controls systems customers,” said David Jemmett, founder and CEO of Cerberus Sentinel. “Carric is an innovative thinker who is well respected by customers for solving and preparing for challenging cybersecurity threats. The team is the very embodiment of our commitment to a culture of security.”

To view the full press release, visit https://ibn.fm/C5R7T

About Cerberus Cyber Sentinel Corporation

Cerberus Sentinel is an industry leader in managed cybersecurity and compliance (“MCCP”) services with its exclusive MCCP+ managed compliance and cybersecurity services plus culture program. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services, and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CerberusSentinel.com.

Cerberus Cyber Sentinel Corporation (CISO), closed Wednesday's trading session at $3.92, up 4.5333%, on 250,297 volume. The average volume for the last 3 months is 244,143 and the stock's 52-week low/high is $2.61/$49.00.

Riot Blockchain Inc. (RIOT)

MarketClub Analysis, Schaeffer's, StocksEarning, InvestorPlace, StockMarketWatch, MarketBeat, TradersPro, Market Intelligence Center Alert, The Street, Zacks, Kiplinger Today, QualityStocks, The Online Investor, BUYINS.NET, Trades Of The Day, TraderPower, Daily Trade Alert, StreetAuthority Daily, Trading Tips, PennyStockLocks, Penny Stock 101, StockRockandRoll, Market Intelligence Center, Investors Alley, InvestorsUnderground, StockEarnings, Money Morning, Promotion Stock Secrets, The Daily Market Alert, StreetInsider and TopPennyStockMovers reported earlier on Riot Blockchain Inc. (RIOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Riot Blockchain (NASDAQ: RIOT), an industry leader in Bitcoin (“BTC”) mining and hosting, today released a production and operations update for June 2022. Among the highlights, the company reported production of 421 BTC in June 2022, an increase of approximately 73% as compared to June 2021 production of 243 BTC. “We are pleased to report that during the month of June, we achieved full operation of all 23,000 S19 series miners in the first immersion-cooled building at our Whinstone Facility, Building F,” said Jason Les, CEO of Riot. “We initially conceived of plans for this immersion-cooled building just twelve months ago, and we are proud of our demonstrated ability to fully execute on our plans on such a rapid timeline. Our Whinstone Facility expansion project now continues on to our second immersion-cooled building, Building G, where the initial miners are deployed and hashing.”

To view the full press release, visit https://ibn.fm/ZYTqN

About Riot Blockchain Inc.

Riot Blockchain’s vision is to be the world’s leading Bitcoin-driven infrastructure platform. The company’s mission is to positively impact the sectors, networks and communities that it touches. Riot believes that the combination of an innovative spirit and strong community partnership allows the company to achieve best-in-class execution and create successful outcomes. Riot is a Bitcoin mining and digital infrastructure company focused on a vertically integrated strategy. The company has Bitcoin mining data center operations in central Texas, Bitcoin mining operations in central Texas and, for the near-term, in upstate New York, and electrical switchgear engineering and fabrication operations in Denver, Colorado. For more information, visit www.RiotBlockchain.com.

Riot Blockchain Inc. (RIOT), closed Wednesday's trading session at $4.53, off by 4.2283%, on 8,250,661 volume. The average volume for the last 3 months is 8.251M and the stock's 52-week low/high is $4.02/$46.28.

HIVE Blockchain Technologies Ltd. (HIVE)

Wall Street Resources, StockMarketWatch, SmarTrend Newsletters, MarketClub Analysis, TradersPro, BUYINS.NET, Marketbeat.com, Jason Bond, QualityStocks, TraderPower, MarketBeat, PennyStocks24, InvestorPlace, OTCPicks, Schaeffer's, StockOodles, Stock Analyzer, StreetInsider, Money Morning, BullRally, CoolPennyStocks, MadPennyStocks, DrStockPick, CRWEPicks, PennyOmega, CRWEWallStreet, HotOTC, Hit and Run Candle Sticks, FeedBlitz, Dynamic Wealth Report, CRWEFinance, PennyToBuck, Wall Street Mover, TopPennyStockMovers, The Street, StockRich, StockHotTips, StockEgg, Rick Saddler, Penny Stock, PoliticsAndMyPortfolio, OTCtipReporter, PennyStockVille, PennyStockScholar, PennyStockProphet, PennyInvest, BestOtc, Penny Sleuth, Penny Pick Finders and Profitable Trader Authority reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HIVE Blockchain Technologies (TSX.V: HIVE) (NASDAQ: HIVE) (FSE: HBF) expects to file its annual report on Form 40-F, which contains its annual audited financial statements, along with its CEO and CFO certifications and management discussion and analysis filing, after the scheduled filing date of June 29, 2022; the reports are for the fiscal year ended March 31, 2022. According to the announcement, HIVE intends to file the required documents on or before July 15, 2022. As a result of the delayed filing, the company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market. The July 1, 2022, notification, which has no immediate effect on the listing or trading of HIVE’s common shares on the Nasdaq Capital Market, officially informed the company that it was not in compliance with Nasdaq listing requirements and notified HIVE that it is required to submit a plan to regain compliance within 60 calendar days. The company noted that the delay is a result of several factors, including the challenge of meeting the shorter filing deadline for non-venture issuers in Canada due to its recent listing on the NASDAQ as well as the rapid increase in the company’s growth and the accompanying increase in the number of transactions. The announcement noted that HIVE does not anticipate difficulties with future filings and is in the process of hiring additional finance staff and making other arrangements to satisfy future filing requirements.

To view the full press release, visit https://ibn.fm/tQLze

About HIVE Blockchain Technologies Ltd.

HIVE Blockchain Technologies IVE Blockchain Technologies Ltd. went public in 2017 as the first cryptocurrency mining company with a green energy and ESG strategy. HIVE is a growth-oriented technology stock in the emergent blockchain industry. The company is building a bridge between the digital currency and blockchain sector and traditional capital markets. HIVE owns state-of-the-art, green energy-powered data center facilities in Canada, Sweden and Iceland, where it sources only green energy to mine on the cloud and HODL both Ethereum and Bitcoin. Since the beginning of 2021, HIVE has held in secure storage the majority of its ETH and BTC coin mining rewards. Those shares provide investors with exposure to the operating margins of digital currency mining, as well as a portfolio of cryptocurrencies such as ETH and BTC. Because HIVE also owns hard assets such as data centers and advanced multiuse servers, the company believes its shares offer investors an attractive way to gain exposure to the cryptocurrency space. For more information about the company, please visit www.HiveBlockchain.com.

HIVE Blockchain Technologies Ltd. (HIVE), closed Wednesday's trading session at $3.23, off by 4.1543%, on 1,210,611 volume. The average volume for the last 3 months is 1.208M and the stock's 52-week low/high is $2.8201/$28.00.

The QualityStocks Company Corner

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

  • Correlate Infrastructure Partners is known for executing portfolio-scale renewable energy and efficiency upgrades across the U.S.
  • With a recent study observing that more CEOs are now prioritizing sustainability, the market is clearly growing for Correlate’s services
  • Correlate helps companies deal with some of the key challenges identified in the study, including concerns about the return on investment and economic benefits, lack of insights from data, inadequate skills, and general technological barriers
  • Correlate funds, designs, engineers, and builds sustainability-focused projects in addition to providing the technical expertise through its team of energy experts, and in a way that makes sustainability compellingly affordable

Sustainability is increasingly gaining prominence as part of the mainstream corporate agenda. A recent study by the Institute for Business Value (“IBV”), a think tank that is part of IBM Corporation (NYSE: IBM), notes that “CEOs who successfully integrate sustainability and digital transformation report a higher average operating margin than their peers.” The study, nonetheless, singled out strategy, committed leadership, and strategic partnerships, as some of the key drivers and differentiators that could enable companies to deal with these hurdles and attain sustainability. “Solving the world’s most vexing social and environmental problems demands strategic collaboration and innovative approaches within and across industries,” an excerpt from the report reads (https://ibn.fm/l6cOX). In Correlate Infrastructure Partners (OTCQB: CIPI), a company with an extensive track record in executing portfolio-scale renewable energy and comprehensive efficiency upgrades across the United States, CEOs looking to solve social and environmental problems find that strategic partner and innovator. 

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Wednesday's trading session at $1.25, up 13.6364%, on 500 volume. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the company’s shareholders voted in favor of all of the proposals submitted for their approval at Flora’s July 5 annual meeting. In addition to the re-election of the company’s six incumbent directors, shareholders also elected Brandon Konigsberg to serve on the board. Further to his responsibilities as a board member, Konigsberg will serve as chair of the audit committee and as a member of the compensation committee. “The addition of Mr. Konigsberg to our board is further testament to our ongoing commitment to fiscal discipline and sound governance. He brings with him exceptional experience in the fields of finance and operations and will assist in helping our organization achieve rapid financial growth and maximize our shareholder value,” said Luis Merchan, Flora’s chairman and CEO. “We are pleased to welcome Mr. Konigsberg as a valued member of our team and look forward to his contributions.” To view the full press release, visit https://ibn.fm/f4Sw8

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $0.6649, up 2.2923%, on 1,700,417 volume. The average volume for the last 3 months is 1.69M and the stock's 52-week low/high is $0.61/$21.45.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash
  • Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”) detection
  • Odyssey Health Inc. is taking its brain concussion solution to a Phase 1 clinical human trial currently with possible progression to Phase 2 before the end of the year
  • The company likewise anticipates it could advance its two device products for FDA submission by year’s end and on to potential commercial development

As 2022 got under way, the biopharma world was trying to predict where the major acquisitions for the year would take place and how much would be spent on M&A, given the cash-flush environment of big-pharma, particularly for those successful in responding to COVID-19, and the patent cliffs many of those companies are facing (https://ibn.fm/IUXaV). Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is optimistic about the trend as the company continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. 

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Wednesday's trading session at $0.27, up 3.8462%, on 114,895 volume. The average volume for the last 3 months is 114,895 and the stock's 52-week low/high is $0.11/$0.65.

Recent News

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

R-Labs, a female-led blockchain-based fintech company, has announced that it managed to raise more than $5 million in a preseed funding round. The Austin, Texas-based financial technology company describes itself as a values-based company building a social impact ecosystem in Web3. R-Labs was cofounded by Geeta Sankappanavar and former Bumble VP of Marketing Chelsea Cain Maclin in early 2022. The startup is looking to leverage the blockchain technology behind the cryptocurrency industry to develop and market digital assets in the controversial metaverse. This preseeding round was led by a variety of major investors including Prodege, AGF and Softbank. Later this year, R-labs plans to launch an NFT project that will arrive on Web3, also referred to as the internet’s third generation, this summer. R-Labs joins a long list of companied like LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) which are focused on bringing blockchain technology to the ordinary person on the street.

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Wednesday's trading session at $0.0922, up 6.5896%, on 49,695 volume. The average volume for the last 3 months is 49,695 and the stock's 52-week low/high is $0.0754/$0.672.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

  • U.S.-based mobile communications technology services provider FingerMotion is a China-focused innovator building revenues in the cell phone and reinsurance markets
  • China recently reinforced its interest in seeing mobile payments and financial technology platforms playing a larger part in its developing economic strategy for strengthening its internal domestic consumerism
  • FingerMotion recently reported annual financial data that showed revenue had grown by 37 percent during last year with 297 percent growth in its big data revenue and 170 percent growth in telecommunications products and services
  • China has an estimated 1.4 billion mobile users, and market analysts predict mobile engagement there will grow at a CAGR of 44.7 percent between 2020 and 2027

Evolving mobile technology services provider FingerMotion (NASDAQ: FNGR) is building a deeper channel for revenue in its services for China’s mobile phone users and big data clients as the nation’s government signals new interest in finding solutions to some of its regulatory concerns for the market in general. 

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Wednesday's trading session at $1.35, even for the day, on 6,478 volume. The average volume for the last 3 months is 6,468 and the stock's 52-week low/high is $1.24/$9.25.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria is a global innovator in drug delivery platforms; its patented DehydraTECH(TM) technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”)
  • Testing confirms that DehydraTECH-processed cannabidiol beverages maintained 93.4% and 78% potency of CBD a full year and two years after production, respectively
  • Lexaria recently signed two agreements with BevNology LLC, an Atlanta-based company with advanced capabilities that support best-in-class beverage formulations
  • The partnership, which also leverages Lexaria’s superior DehydraTECH-CBD nanoemulsification formulation and processing techniques, could make industry-leading beverage products a reality for many brands 

In this year’s letter to shareholders, Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka acclaimed the company’s research and development achievements which had resulted in remarkable stability of DehydraTECH(TM)-processed cannabidiol (“CBD”) beverages. One year after production, Bunka wrote, “bottled consumer beverage contained a remarkable 93.4% potency of CBD. We also showed less than 1% variability of CBD potency within the beverage, a concept of critical importance when delivering drugs in an aqueous solution” (https://cnw.fm/H4ndc).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $2.72, off by 6.2069%, on 109,733 volume. The average volume for the last 3 months is 109,733 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, will be presenting at the July 6, 2022, Emerging Growth Investor Conference. This elite event features rapidly growing public companies; each company presents a 30–45-minute overview to those in attendance. PBIO president and CEO Mr. Richard T. Schumacher will represent Pressure BioSciences at the event; his presentation, which will include a Q&A session, is slated to begin at 10:30 a.m. ET. The presentation will include information about the company’s recent announcement of the contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use. The company invites investors, analysts and advisors to attend the session. For more than a decade, EmergingGrowth.com has been presenting these events, establishing itself as a leading, independent small-cap media portal. The conference provides unparalleled content in identifying emerging growth companies and markets that are sometimes overlooked by the investment community. To register for and attend the event, visit https://ibn.fm/UuGB5. To view the full press release, visit https://ibn.fm/cPRRG

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $1.6, off by 1.8405%, on 2,500 volume. The average volume for the last 3 months is 2,500 and the stock's 52-week low/high is $1.51/$4.98.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

In the past few years, archaeological studies have revealed that ancient people may have used recreational drugs in their rituals. According to archaeologists, ancient Andean civilizations may have used hidden passageways to take part in rituals that involved psychedelic drugs. Archaeologists on a dig in Peru discovered a network of hidden galleries and passageways deep inside an ancient temple complex called Chavin de Huántar, which is located in the Peruvian Andes. The archaeologists believe that this complex of passageways and chambers was used in religious rituals that may have involved psychedelic drugs. These hidden structures had been sealed off from the public for approximately 3,000 years. The possibility that ancients in Peru used psychedelics during their worship ceremonies means that these substances being studied for their medicinal potential by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) have an even longer history of use than had previously been thought.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.57, off by 1.5544%, on 297,527 volume. The average volume for the last 3 months is 280,666 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

  • Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash
  • Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”) detection
  • Odyssey Health Inc. is taking its brain concussion solution to a Phase 1 clinical human trial currently with possible progression to Phase 2 before the end of the year
  • The company likewise anticipates it could advance its two device products for FDA submission by year’s end and on to potential commercial development

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) s a growth-stage technology company engaged in providing energy-efficient solutions that are commercially viable and sustainable. Their flagship product, a containerized green ammonia production system, can be used across a spectrum of industries, with special significance for agricultural fertilizers, and offers innovative solutions that address environmental concerns and unpredictable supply chain risks.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Wednesday's trading session at $0.113, off by 3.9116%, on 201,120 volume. The average volume for the last 3 months is 201,120 and the stock's 52-week low/high is $0.09/$0.24.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Neurological conditions such as Huntington’s and Alzheimer’s disease as well as spinal cord injuries can be nigh impossible to treat. In most cases, all doctors and caregivers can do is reduce the severity of the symptoms and find ways to improve a patient’s quality of life. Consequently, scientists are always looking for more effective treatments for the millions of people in the world who live with neurological disorders. Researchers studying the brain and how it responds to disease and injury have now mapped a brain cell regulation mechanism that could allow them to develop novel treatments for brain disorders and spinal cord injuries. Many more entities, such as Silo Pharma Inc. (OTCQB: SILO), are conducting R&D aimed at developing novel interventions that will improve the treatment outcomes for patients with different neurological ailments. A time may come when most patients can have their symptoms halted or even reversed.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $0.1022, off by 7.0909%, on 22,289 volume. The average volume for the last 3 months is 22,289 and the stock's 52-week low/high is $0.0892/$0.2489.

Recent News

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

  • Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
  • Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
  • Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Wednesday's trading session at $0.014, up 2.1898%, on 108,612 volume. The average volume for the last 3 months is 108,612 and the stock's 52-week low/high is $0.01/$0.064.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $4.91, up 0.614754%, on 3,230,574 volume. The average volume for the last 3 months is 3.201M and the stock's 52-week low/high is $4.32/$11.39.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.